Molecular Cardiology Research Institute (MCRI)
Cardio-Oncology Research Group
The Cardio-Oncology Research Group brings together basic scientists from the Molecular Cardiology Research Institute (MCRI) with scientists and clinician-investigators from the Cardiology and Oncology Divisions at Tufts Medical Center and at the Cummings School of Veterinary Medicine at Tufts University as well as statisticians and population researchers in the Institute for Clinical Research and Health Policy Studies (ICRHPS) and the Tufts Clinical and Translational Sciences Institute (CTSI). With the explosion in novel cancer therapies, there has been a rise in cardiovascular side effects of these therapies that is limiting quality of life and life expectancy of cancer survivors.
The goal of the Cardio-Oncology Research Group is to advance our understanding of genetic, biological, and clinical factors that contribute to the cardiovascular toxicity of cancer therapies, to identify biomarkers of toxicity that can be employed to improve clinical care, and to determine therapies to mitigate the side effects of cancer treatment. The group is using a one-health approach to develop a cross species platform that includes cellular and model organisms, canine cancer patients, and human cancer patients to investigate novel mechanisms, biomarkers, and therapies to improve cardiovascular outcomes in cancer patients.